Case Western Reserve University

Boston University

Caritas St. Elizabeth's Medical Center of Boston, Inc.

St. Elizabeth's Medical Center

Scimed Life Systems, Inc.

Kenneth Walsh

David H Gorski

Yuichi Oshima

Noriyuki Ouchi

Maria Palasis

Patrice Denefle

Jeffrey M Isner

Didier Branellec

Jose Fuster

As demonstrated herein, a preferential and progressive expansion of a subset of hematopoietic cells bearing somatic mutations in TET2 leads to pro-inflammatory IL-1&#x3b2; signaling at multiple levels, including increased IL-1&#x3b2; transcription, increased NLRP3 inflammasome-mediated IL-1&#x3b2; secretion, and increased IL-1-Receptor 1-mediated IL-1&#x3b2; signaling. Accordingly, provided herein are compositions, methods, and assays for modulating TET2 mutation-mediated IL-1&#x3b2; (interleukin-1&#x3b2;) proinflammatory activity, particularly when caused by somatic mutations in TET2.

Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.

Method of treating ischemic injury with follistatin-like 1 polypeptide

This invention relates to methods and compositions for the treatment of apoptotic cell-death. In particular the invention relates to Akt molecules and their use in inhibiting apoptotic cell-death in cardiomyocytes, skeletal myocytes and/or vascular endothelial cells. In view of these discoveries, Akt molecules can be used to inhibit apoptotic cell-death of any of the foregoing cells, and in particular, to treat conditions (e.g., myocardial infarction) that result in increased apoptotic cell-death of cardiomyocytes, skeletal myocytes and/or vascular endothelial cells.

Akt compositions for enhancing survival of cells

A novel growth arrest homeobox gene has been discovered and the nucleotide sequences have been determined in both the rat and the human. The expression of the novel homeobox gene inhibits vascular smooth muscle cell growth. The growth arrest homeobox gene hereinafter referred to as the 'Gax gene' and its corresponding proteins are useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty.

Growth arrest homebox gene

Growth arrest homeobox gene

This invention relates to methods and compositions for the treatment of conditions associated with vascular insufficiency, and to methods and compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to HMG CoA reductase inhibitors and their use in promoting angiogenesis in vivo and in activating Akt in vascular endothelial cells in vitro and in vivo.

HMG CoA reductase inhibitors for promoting angiogenesis

A method of site-specifically delivering a therapeutic agent to a target location within a body cavity, vasculature or tissue. The method comprises the steps of providing a medical device having a substantially saturated solution of therapeutic agent associated therewith; introducing the medical device into the body cavity, vasculature or tissue; releasing a volume of the solution of therapeutic agent from the medical device at the target location at a pressure of from about 0 to about 5 atmospheres for a time of up to about 5 minutes; and withdrawing the medical device from the body cavity, vasculature or tissue. In another aspect, the present invention includes a system for delivering a therapeutic agent to a body cavity, vasculature or tissue, comprising a medical device having a substantially saturated solution of the therapeutic agent associated therewith.

High efficiency local drug delivery

A novel growth arrest homeobox gene has been discovered and the nucleotide sequences have been determined in both the rat and the human. The expression of the novel homeobox gene inhibits vascular smooth muscle cell growth. The growth arrest homeobox gene hereinafter referred to as the &ldquo;Gax gene&rdquo; and its corresponding proteins are useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty.

Methods and compositions for reducing or preventing the proliferation of vascular smooth muscle cells are provided. The method involves the step of administering an isolated GATA-6 molecule to a subject to prevent or reduce vascular smooth muscle cell proliferation. The isolated GATA-6 molecule can be a GATA-6 nucleic acid or a GATA-6 protein.

GATA-6 transcription factor: compositions and methods

A method for treating vascular injury, particularly vascular injury resulting from restenosis following angioplasty, and vascular remodeling is provided. The method involves administering to subjects in need of such treatment an effective amount of a Fas ligand molecule.

Fas ligand compositions for treatment of proliferative disorders

The present invention relates to replication defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.

Growing community of inventors

Carlisle, MA, United States of America

Kenneth Walsh